Inovio Pharmaceuticals Inc（INO）财务数据INOInovio Pharmaceuticals Inc

Evaluating the bottom line, Inovio Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -409.87%, provide a clear picture of how effectively INO converts its operational activities into shareholder value.

In the context of the broader market, INO competes directly with industry leaders such as LENZ and TNXP. With a market capitalization of $118.91M, it holds a leading position in the sector. When comparing efficiency, INO's gross margin of N/A stands against LENZ's 94.90% and TNXP's 94.81%. Such benchmarking helps identify whether Inovio Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Inovio's total revenue for Q4 2024 was $116,994, but it has reported significant net losses, with a net income of -$19,381,679 for the same quarter. The gross margin has been 100% for the last reported quarters, but it is expected to drop to 0% in future quarters, indicating potential challenges ahead.